Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Sanofi to buy vaccines biotech group Protein Sciences

Written by: | no-reply@reuters.com | Dated: Tuesday, July 11th, 2017

 

French drugmaker and healthcare group Sanofi is to buy privately-held U.S. vaccines biotech company Protein Sciences for an initial amount of $650 million, as Sanofi steps up its acquisition program after recently missing two large deals.

Under the terms of the agreement, Sanofi will make an upfront payment of $650 million for Protein Sciences, and pay up to $100 million upon the achievement of certain milestones.

“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi executive vice president and head of Sanofi Pasteur, the company’s vaccines arm. 

Sanofi missed out to Johnson & Johnson on buying Switzerland’s biotech Actelion in January – a $30 billion deal – and was also beaten in August last year by a $14 billion bid for cancer specialist Medivation from Pfizer.

 

(Reporting by Sudip Kar-Gupta)

 

Reuters source:

http://www.reuters.com/article/us-protein-sciences-m-a-sanofi-fr-idUSKBN19W0CP

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2017 Focus: Payers, Biotech, HBA WOTY and more!

Subscribe

Ad Right Bottom

Main Navigation